E. Fraile-Bethencourt

This study shows that activating RIG-I in tumor cells enhances anti-tumor immunity and improves response to checkpoint therapy, suggesting a strategy for cancer vaccines.

This study identifies MEG9 as a cytoprotective lncRNA in endothelial cells that modulates angiogenesis and vascular homeostasis in response to DNA damage.

The paper identifies HDAC inhibitors as activators of RIG-I signaling through a cell-based screen and shows their potential in enhancing immune responses in cancer.